Clinical trials in Russia in 2026 remain one of the most expensive stages in bringing a new pharmaceutical product or medical device to market. At the same time, project costs may vary by dozens of times - from several million rubles for a local bioequivalence study to hundreds of millions or even billions of rubles for international multicenter Phase III programs.
The cost of a clinical trial in Russia depends not only on the number of patients. The final budget is influenced by:

• study phase;
• therapeutic area;
• protocol complexity;
• duration of follow-up;
• regulatory requirements;
• level of project digitalization;
• scope of laboratory diagnostics;
• trial format.

For pharmaceutical companies and biotechnology developers, understanding the clinical trial budget is critically important already at the drug registration planning stage.
What Influences the Cost of a Clinical Trial?
Main pricing factors include:

• study phase;
• number of research centers;
• number of patients;
• protocol complexity;
• scope of laboratory diagnostics;
• need for hospitalization;
• use of electronic data management systems;
• monitoring and auditing;
• statistical data processing;
• pharmacovigilance;
• project duration.

For example, a Phase III oncology trial is almost always more expensive than a cardiology or dermatology project due to:

• high treatment costs;
• complex diagnostics;
• long-term patient follow-up;
• large volumes of data;
• increased safety requirements.

What Is Included in the Cost of a Turnkey Clinical Trial?
A full-service turnkey clinical trial usually includes:

• protocol development;
• regulatory support;
• interaction with the Ministry of Health and ethics committees;
• patient recruitment;
• trial monitoring;
• data management;
• biostatistics;
• laboratory testing;
• pharmacovigilance;
• preparation of the final clinical study report.

This is why the total project cost is determined not only by payments to research centers, but also by numerous operational and regulatory processes.
Average Cost of Clinical Trials in Russia in 2026
Phase I
Phase I involves the first studies of a drug in humans, most often in healthy volunteers.
Average cost:

• from RUB 5 million to RUB 80 million.

For bioequivalence studies:

• from RUB 6 million to RUB 25 million.

Cost factors include:

• number of volunteers;
• complexity of the study design;
• volume of pharmacokinetic analyses;
• need for inpatient facilities;
• laboratory capabilities.

Recommendation
When selecting a research center, it is important to evaluate not only the cost of services, but also the quality of the bioanalytical laboratory, experience with early-phase studies, and the speed of volunteer recruitment.
Phase II
Phase II evaluates:

• drug efficacy;
• optimal dosage;
• treatment safety.

Average budget:

• from RUB 50 million to RUB 250 million.

Costs increase significantly if the study is conducted:

• across multiple research centers;
• in patients with rare diseases;
• using biomarkers;
• in oncology or cell therapy.

Recommendation
At Phase II, proper protocol design is especially important. Errors in study design may lead to the failure of a promising drug and multimillion-ruble losses.
Phase III
Phase III is the largest and most expensive stage of clinical development.
Typical budget in Russia:

• from RUB 180 million to RUB 2–3 billion.

The high cost is associated with:

• large patient populations;
• international trial formats;
• long-term follow-up;
• complex diagnostics;
• extensive monitoring;
• increased data quality requirements.

Recommendation
For large-scale projects, it is especially important to choose research centers with experience in international studies and successful inspection histories.
Phase IV and Real-World Evidence Studies
After drug registration, companies continue to study:

• long-term safety;
• treatment effectiveness;
• rare adverse reactions;
• outcomes in real-world clinical practice.

Average budget:

• from RUB 7 million to RUB 150 million.

Such studies are becoming especially востребованными in:

• oncology;
• rare disease treatment;
• label expansion programs.

How Much Does One Patient Cost in a Clinical Trial?
In 2026, the average cost per patient in Russia is:
The most expensive areas remain:

• cell therapy;
• genetic medicines;
• orphan diseases;
• personalized medicine.

How to Reduce Clinical Trial Costs?
It is impossible to eliminate expenses completely, but proper project organization can significantly optimize the budget.
Key Recommendations
Develop the Protocol Carefully
The simpler and more realistic the study design, the:

• faster patient recruitment;
• lower the risk of errors;
• cheaper the project execution.

Choose Experienced Research Centers
A strong research site:

• launches projects faster;
• recruits patients more effectively;
• reduces the risk of protocol deviations.

Use Digital Tools
Modern systems help to:

• accelerate monitoring;
• improve data quality;
• reduce administrative costs.

Conduct Preliminary Project Assessment
Analyzing patient availability and timeline feasibility helps avoid serious financial losses in the future.
Frequently Asked Questions
How Much Does a Bioequivalence Study Cost in Russia?
On average, from RUB 5-6 million to RUB 25 million, depending on the complexity of the drug and the scope of bioanalytics.
How Long Does a Clinical Trial Last?
From 3-6 months for bioequivalence studies to 2-5 years for large Phase III trials.
What Has the Greatest Impact on Cost?
The number of patients, protocol complexity, duration of follow-up, and volume of laboratory diagnostics.
Why Are Oncology Trials More Expensive?
Due to complex diagnostics, long-term follow-up, high treatment costs, and increased safety requirements.
Conclusion
In 2026, the cost of a clinical trial in Russia may range:

• from RUB 5-10 million for local projects,
• to several billion rubles for international multicenter programs.

The more innovative the drug and the more complex the study design, the higher the project budget. Expenses are growing especially rapidly in:

• oncology;
• cell therapy;
• genetic research;
• projects involving long-term patient follow-up.

At the same time, not only the cost of the study matters, but also the quality of its organization. Mistakes at the protocol development stage, during the selection of research centers, or in data management may lead to serious delays and additional expenses.
Our clinic and research team help pharmaceutical companies and biotechnology developers conduct turnkey clinical trials - from document preparation to issuance of the final clinical study report.
We provide:

• rapid research center activation;
• professional regulatory support;
• stable patient recruitment;
• modern research infrastructure;
• transparent budgeting and timeline control at every stage of the project.

If you need to estimate the cost of a clinical trial in Russia or select the optimal project model, our team is ready to offer an individualized solution tailored to your product’s objectives, timelines, and regulatory requirements.